Japan's Nichirei will register Biocartis' Idylla MDx oncology products with the Japanese Ministry of Health, Labor and Welfare.
The two firms will provide €14M ($16.2 million) of equity funding to commercialize the Idylla platform in the Chinese market.
LabCorp will be able to develop and commercialize the test for patients with an elevated PSA to determine their risk of having clinically significant prostate cancer.
Dian selected the MassArray system as its platform of choice for molecular genetic testing and will commercialize it and Agena's DNA applications and products.
Malaysia-based ScienceVision has agreed to commercialize and distribute the PierianDx Clinical Genomics Workspace platform in Southeast Asian countries.
CareDx has paid Illumina a $5 million initial payment and will pay royalties in the mid-single to low-double digits on sales of future commercialized products.
Running on the Biocartis Idylla platform, Immunexpress' Septicyte test will detect sepsis in patients in as little as an hour.
Biocartis will help develop and commercialize Immunexpress' Septicyte test to run on the Idylla platform.
The two companies intend to develop and commercialize several cancer and NIPT assays using a combination of their technologies.
GoPath has gained non-exclusive rights to commercialize a colorectal cancer test for the US and Canada based on IntegraGen's miR-31-3p biomarker.
New results from the NASA Twins Study indicate that the immune system may rev up when in space, the Washington Post reports.
Kelvin Droegemeier, the new science advisor, spoke at the American Association for the Advancement of Science meeting, Geekwire reports.
In PNAS this week: whole-genome assembly for the white shark, paper-based microfluidic method for detecting the malaria parasite, and more.
The World Health Organization has announced the members of its gene-editing committee, according to NPR.